1. Australia Stocks

  2. •

    Healthcare

  3. •

    Medical - Healthcare Information Services
Cogstate Limited

Cogstate Limited

COGZF
Cogstate LimitedUS flagOther OTC
1.70
USD
-0.15
- -
291.37MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
0.15
0.13
0.12
0.18
0.24
0.25
0.18
0.15
0.19
0.26
0.23
0.25
0.3
Basic EPS, GAAP
-0.02
-0.04
-0.04
0.02
-0.01
- -
-0.02
-0.01
0.03
0.04
0.02
0.03
0.06
Free Cash Flow per Basic Share
-0.03
-0.05
-0.04
0.01
0.01
-0.02
-0.02
-0.02
-0.02
-0.02
-0.01
-0.01
-0.02
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.09
0.12
0.07
0.09
0.09
0.11
0.09
0.11
0.14
0.19
0.21
0.23
0.25
Tangible Book Value per Share
0.08
0.11
0.07
0.09
0.09
0.08
0.04
0.06
0.08
0.13
0.15
0.18
0.22
Basic Weighted Avg Shares
77
91
100
111
114
115
119
159
170
173
173
172
171
Sales/Revenue/Turnover
11
12
12
20
27
29
22
24
33
45
40
43
51
Operating Margin (%)
-19.62
-38.89
-26.96
2.57
-1.41
0.63
-26.8
-8.13
11.71
24.14
5.57
14.21
21.25
Depreciation Expense
1
1
1
1
1
1
- -
2
2
2
3
3
3
Net Income, GAAP
-2
-4
-4
2
-1
-1
-2
-1
5
8
4
5
10
Effective Tax Rate (%)
- -
- -
- -
- -
- -
632.79
- -
- -
10.09
29.67
- -
23.26
27.06
Profit Margin (%)
-15.7
-31.7
-31.49
9.69
-2.36
-1.95
-11.43
-5.56
16.01
16.72
8.82
12.55
19.97
Working Capital
5
8
6
6
7
6
- -
3
15
24
26
31
37
LT Debt
- -
- -
- -
- -
- -
- -
- -
2
1
1
- -
- -
- -
Total Equity
8
12
8
10
11
12
10
16
22
33
38
41
48
Return on Invested Capital (%)
- -
- -
- -
- -
- -
-8.59
- -
- -
15.39
26.4
- -
11.89
17.35
Return on Capital (%)
- -
- -
- -
- -
- -
-8.56
- -
- -
22.4
25.58
- -
14.42
24.41
Return on Common Equity (%)
-22.39
-41.98
-43.92
23.24
-6.37
-5.03
-21.12
-9.2
25.74
26.8
10.33
14.52
24.61

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.81%
25.26%
17.05%
Free Cash Flow
-35.55%
4.7%
62.79%
Net Income, GAAP
-36.75%
-73.54%
86.15%
Sales/Revenue/Turnover
17.86%
17.98%
17%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
40
2024
- -
- -
- -
- -
43
2025
- -
- -
- -
- -
51

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.02
2024
- -
- -
- -
- -
0.03
2025
- -
- -
- -
- -
0.06

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Bradley John O'Connor
Full Time Employees
147
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Address
161 Collins Street Melbourne VIC Australia 3000
IPO Date
Apr 5, 2010
Website
cogstate.com
Similar Companies
NantHealth, Inc. (NH)
Founders Bay Holdings (FDBH)
Surgical Science Sweden AB (publ) (SUS.ST)
Cloud DX Inc. (CDXFF)
MSP Recovery, Inc. (MSPRV)
Medical Cannabis Payment Solutions, Inc. (REFG)
Business
Cogstate Limited (OTC: COGZF) provides computerized cognitive assessments for clinical trials, clinical practice, and healthcare settings worldwide. The company offers a suite of proprietary, validated digital tests including the Cogstate Brief Battery for screening mild cognitive impairment and Alzheimer's disease; the Cogstate Alzheimer's Battery for early detection and monitoring of Alzheimer's pathology; computerized neuropsychological tests for schizophrenia and other CNS disorders; and the Cognigram platform for remote cognitive screening in primary care. These products support pharmaceutical companies, contract research organizations, healthcare providers, and academic researchers in measuring cognitive function objectively and reliably; services encompass test administration, data management, and regulatory-compliant reporting. Founded in 1999 and headquartered in Melbourne, Australia, Cogstate operates primarily in North America, Europe, and Australia, with a focus on central nervous system therapeutics and neurology segments targeting biotech, pharma, and telehealth markets.

Company News

APIChat

  • seekingalpha.com

    Cogstate Limited (COGZF) Q2 2026 Earnings Call Transcript

  • seekingalpha.com

    Cogstate Limited (COGZF) FY 2025 Earnings Call Transcript

  • seekingalpha.com

    Cogstate Limited (COGZF) Q2 2025 Earnings Call Transcript

  • globenewswire.com

    Cogstate Expands Alzheimer's Disease Leadership with Appointment of Dr. Kaycee Sink, as Chief Medical Officer

  • seekingalpha.com

    Cogstate Limited (COGZF) Q4 2024 Earnings Call Transcript

  • seekingalpha.com

    Cogstate Limited (COGZF) Q4 2022 Earnings Call Transcript

  • seekingalpha.com

    Cogstate Limited (COGZF) CEO Brad O'Connor on Q4 2022 Results - Earnings Call Transcript